Results 61 to 70 of about 15,364 (179)

Platelet Satellitism Causing Apparent Loss of Response to Eltrombopag in a Patient With Immune Thrombocytopenia

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Torsten Ebeling   +3 more
wiley   +1 more source

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2023
Monica Carpenedo   +3 more
doaj   +1 more source

Thrombopoietin ameliorates doxorubicin-induced toxicities in H9c2 myocardiocytes by inhibiting oxidative stress through the SIRT1/p38 MAPK signaling pathway

open access: yesAsian Pacific Journal of Tropical Biomedicine
Objective: To explore whether thrombopoietin can exert a protective effect against doxorubicin-induced cardiotoxicity by modulating the sirtuin 1 (SIRT1) signaling pathway.
Xu-Han Zuo   +8 more
doaj   +1 more source

Trace of chestnut on platelets proliferation in male rats: In vivo study [PDF]

open access: yesIraqi Journal of Veterinary Sciences
The study seeks the efficacy of the chestnut extract on platelet proliferation and its function in guaranteeing more tangible physiological information about unexpected mortality caused by thrombus formation.
Hiyam N. Maty
doaj   +1 more source

Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes

open access: yesJournal of Veterinary Internal Medicine
Background Romiplostim, a thrombopoietin analog, is commonly used to treat immune‐mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Min‐Ok Ryu   +5 more
doaj   +1 more source

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin

open access: yesFrontiers in Immunology
BackgroundEltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).MethodsForty-one HSCT patients received ...
Yahan Li   +14 more
doaj   +1 more source

Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?

open access: yesPlatelets, 2019
Chronic liver disease (CLD) alters normal hemostatic and thrombotic systems via multiple mechanisms including reduced platelet function and number, leading to challenging peri-operative planning.
Sven R. Olson   +5 more
doaj   +1 more source

Identification of MPL R102P Mutation in Hereditary Thrombocytosis

open access: yesFrontiers in Endocrinology, 2017
The molecular basis of hereditary thrombocytosis is germline mutations affecting the thrombopoietin (TPO)/TPO receptor (MPL)/JAK2 signaling axis. Here, we report one family presenting two cases with a mild thrombocytosis.
Christine Bellanné-Chantelot   +15 more
doaj   +1 more source

Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune‐Mediated Thrombocytopenia

open access: yesJournal of Veterinary Internal Medicine
A 2‐year‐old female spayed British Shorthair cat was diagnosed with immune‐mediated thrombocytopenia (ITP) after presenting with a 3‐week history of gastrointestinal bleeding and anemia.
Josh M. Kennils, Helen E. Wilson
doaj   +1 more source

Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey

open access: yesBiomolecules
Thrombopoietin, the primary regulator of blood platelet production, was postulated to exist in 1958, but was only proven to exist when the cDNA for the hormone was cloned in 1994.
Kenneth Kaushansky
doaj   +1 more source

Home - About - Disclaimer - Privacy